Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-21-003509
Filing Date
2021-11-12
Accepted
2021-11-12 08:38:49
Documents
34
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q zk2126774.htm   iXBRL 10-Q 745506
2 EXHIBIT_31-1 exhibit_31-1.htm EX-31.1 12663
3 EXHIBIT_31-2 exhibit_31-2.htm EX-31.2 12771
4 EXHIBIT_32-1 exhibit_32-1.htm EX-32.1 6460
5 EXHIBIT_32-2 exhibit_32-2.htm EX-32.2 6020
  Complete submission text file 0001178913-21-003509.txt   2261033

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cmmb-20210930.xsd EX-101.SCH 20673
7 XBRL CALCULATION FILE cmmb-20210930_cal.xml EX-101.CAL 24379
8 XBRL DEFINITION FILE cmmb-20210930_def.xml EX-101.DEF 68490
9 XBRL LABEL FILE cmmb-20210930_lab.xml EX-101.LAB 140341
10 XBRL PRESENTATION FILE cmmb-20210930_pre.xml EX-101.PRE 113695
11 EXTRACTED XBRL INSTANCE DOCUMENT zk2126774_htm.xml XML 172803
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38807 | Film No.: 211399984
SIC: 2834 Pharmaceutical Preparations